See more : Paion AG (0NF3.L) Income Statement Analysis – Financial Results
Complete financial analysis of Cortexyme, Inc. (CRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cortexyme, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- i2S SA (ALI2S.PA) Income Statement Analysis – Financial Results
- Anavex Life Sciences Corp. (AVXL) Income Statement Analysis – Financial Results
- Mastercard Incorporated (0R2Z.L) Income Statement Analysis – Financial Results
- Young Poong Corporation (000670.KS) Income Statement Analysis – Financial Results
- Soosan Heavy Industries Co., Ltd. (017550.KS) Income Statement Analysis – Financial Results
Cortexyme, Inc. (CRTX)
About Cortexyme, Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -90.32M | -78.89M | -39.17M | -11.47M | -10.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.95M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 373.00K | 2.04M | 2.19M | 600.00K | -222.00K |
| Net Income | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| EPS Diluted | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
CRTX Stock Price Increased 47.32%: Why It Happened
The stock price of Cortexyme Inc (NASDAQ: CRTX) increased 47.32%. This is why it happened.
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Source: https://incomestatements.info
Category: Stock Reports